Skip to main content

Table 1 Characteristics of studies included in the meta-analysis

From: Effect of combined pulmonary fibrosis and emphysema on patients with connective tissue diseases and systemic sclerosis: a systematic review and meta-analysis

Study/year

Country

Number of subjects with CTD (men/women)

Age of subjects (years; mean ± SD)

CTD

Diagnosis method of ILD

NOS score

Total

CPFE

ILD without emphysema

CPFE

ILD without emphysema

Antoniou et al./2016 [3]

UK

333 (74/259)

41 (18/23)

292 (56/236)

53.1 ± 15.1

54.4 ± 12.8

SSc

HRCT

8

Ariani et al./2019 [4]

Italy

239 (52/187)

43 (16/27)

196 (36/160)

57.7 ± 14.3

59.4 ± 13.49

SSc

CT

3

Champtiaux et al./2018 [5]

France

108 (40/68)

36 (27/9)

72 (13/59)

48.75 ± 17.02

46.75 ± 17.6

SSc

HRCT

8

Cottin et al./2011 [6]

France

68 (33/35)

34 (23/11)

34 (10/24)

57 ± 11

65 ± 10

RA 18 (53%)

SSc 10 (29%)

MCTD 2 (6%)

Overlapping CTD 2 (6%)

Sjogren’s syndrome 1 (3%)

Polymyositis 1 (3%)

HRCT

8

Jacob et al./2018 [7]

South Korea and UK

245 (110/135)

129 (85/44)

116 (25/91)

63 (median)

62 (median)

RA

CT

8

Yamakawa et al./2018 [8]

Japan

21 (3/18)

16 (2/14)

5 (1/4)

60.5 ± 10.5

59.8 ± 11.7

SSc

HRCT

8

Total

1014 (312/702)

299 (171/128)

715 (141/574)

HRCT

8

  1. CTD connective disease, CPFE connective disease and combined pulmonary fibrosis and emphysema, ILD interstitial lung disease, NOS Newcastle-Ottawa Scale, SSs systemic sclerosis, RA rheumatoid arthritis, MCTD mixed connective tissue disease, CT computed tomography, HRCT high-resolution computed tomography